Speak directly to the analyst to clarify any post sales queries you may have.
The publisher has been monitoring the chemotherapy-induced nausea and vomiting drugs market and it is poised to grow by $ 759.79 million during 2021-2025, progressing at a CAGR of 6.08% during the forecast period. The report on the chemotherapy-induced nausea and vomiting drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the growing cancer population and growing preference for chemotherapy drugs in developing countries.
The chemotherapy-induced nausea and vomiting drugs market analysis includes the therapy segment and geographic landscape.
The chemotherapy-induced nausea and vomiting drugs market is segmented as below:
By Geographical Landscape
- North America
- Europe
- Asia
- ROW
By Therapy
- Serotonin receptor antagonists
- NK1 receptor antagonists
- Others
This study identifies the approval of new drugs as one of the prime reasons driving the chemotherapy-induced nausea and vomiting drugs market growth during the next few years.
The report on chemotherapy-induced nausea and vomiting drugs market covers the following areas:
- Chemotherapy-induced nausea and vomiting drugs market sizing
- Chemotherapy-induced nausea and vomiting drugs market forecast
- Chemotherapy-induced nausea and vomiting drugs market industry analysis
The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading chemotherapy-induced nausea and vomiting drugs market vendors that include Aurobindo Pharma Ltd., Cipla Inc., Dr. Reddys Laboratories Ltd., GlaxoSmithKline Plc, Heron Therapeutics Inc., Merck and Co. Inc., Glenmark Pharmaceuticals Ltd., Mylan NV, Novartis AG, and Teva Pharmaceutical Industries Ltd. Also, the chemotherapy-induced nausea and vomiting drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provides a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
Executive Summary- Market overview
Market Landscape
- Market ecosystem
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2020
- Market outlook: Forecast for 2020 - 2025
Five Forces Analysis
- Five forces analysis 2020 & 2025
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Therapy
- Market segments
- Comparison by Therapy
- Serotonin receptor antagonists - Market size and forecast 2020-2025
- NK1 receptor antagonists - Market size and forecast 2020-2025
- Others - Market size and forecast 2020-2025
- Market opportunity by Therapy
Customer landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2020-2025
- Europe - Market size and forecast 2020-2025
- Asia - Market size and forecast 2020-2025
- ROW - Market size and forecast 2020-2025
- Key leading countries
- Market opportunity By Geographical Landscape
- Market drivers
- Market challenges
- Market trends
Vendor Landscape
- Overview
- Vendor landscape
- Landscape disruption
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- Aurobindo Pharma Ltd.
- Cipla Inc.
- Dr. Reddys Laboratories Ltd.
- GlaxoSmithKline Plc
- Glenmark Pharmaceuticals Ltd.
- Heron Therapeutics Inc.
- Merck and Co. Inc.
- Mylan NV
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
List of Exhibits
- Key Finding 1
- Key Finding 2
- Key Finding 3
- Key Finding 5
- Key Finding 6
- Key Finding 7
- Key Finding 8
- Parent market
- Market characteristics
- Offerings of vendors included in the market definition
- Market segments
- Global - Market size and forecast 2020 - 2025 ($ million)
- Global market: Year-over-year growth 2020 - 2025 (%)
- Five forces analysis 2020 & 2025
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition - Five forces 2020
- Therapy - Market share 2020-2025 (%)
- Comparison by Therapy
- Serotonin receptor antagonists - Market size and forecast 2020-2025 ($ million)
- Serotonin receptor antagonists - Year-over-year growth 2020-2025 (%)
- NK1 receptor antagonists - Market size and forecast 2020-2025 ($ million)
- NK1 receptor antagonists - Year-over-year growth 2020-2025 (%)
- Others - Market size and forecast 2020-2025 ($ million)
- Others - Year-over-year growth 2020-2025 (%)
- Market opportunity by Therapy
- Customer landscape
- Market share By Geographical Landscape 2020-2025 (%)
- Geographic comparison
- North America - Market size and forecast 2020-2025 ($ million)
- North America - Year-over-year growth 2020-2025 (%)
- Europe - Market size and forecast 2020-2025 ($ million)
- Europe - Year-over-year growth 2020-2025 (%)
- Asia - Market size and forecast 2020-2025 ($ million)
- Asia - Year-over-year growth 2020-2025 (%)
- ROW - Market size and forecast 2020-2025 ($ million)
- ROW - Year-over-year growth 2020-2025 (%)
- Key leading countries
- Market opportunity By Geographical Landscape ($ million)
- Impact of drivers and challenges
- Vendor landscape
- Landscape disruption
- Industry risks
- Vendors covered
- Market positioning of vendors
- Aurobindo Pharma Ltd. - Overview
- Aurobindo Pharma Ltd. - Product and service
- Aurobindo Pharma Ltd. - Key offerings
- Aurobindo Pharma Ltd. - Key customers
- Aurobindo Pharma Ltd. - Segment focus
- Cipla Inc. - Overview
- Cipla Inc. - Business segments
- Cipla Inc. - Key offerings
- Cipla Inc. - Key customers
- Cipla Inc. - Segment focus
- Dr. Reddys Laboratories Ltd. - Overview
- Dr. Reddys Laboratories Ltd. - Business segments
- Dr. Reddys Laboratories Ltd. - Key offerings
- Dr. Reddys Laboratories Ltd. - Key customers
- Dr. Reddys Laboratories Ltd. - Segment focus
- GlaxoSmithKline Plc - Overview
- GlaxoSmithKline Plc - Business segments
- GlaxoSmithKline Plc - Key offerings
- GlaxoSmithKline Plc - Key customers
- GlaxoSmithKline Plc - Segment focus
- Glenmark Pharmaceuticals Ltd. - Overview
- Glenmark Pharmaceuticals Ltd. - Product and service
- Glenmark Pharmaceuticals Ltd. - Key offerings
- Glenmark Pharmaceuticals Ltd. - Key customers
- Glenmark Pharmaceuticals Ltd. - Segment focus
- Heron Therapeutics Inc. - Overview
- Heron Therapeutics Inc. - Product and service
- Heron Therapeutics Inc. - Key offerings
- Heron Therapeutics Inc. - Key customers
- Heron Therapeutics Inc. - Segment focus
- Merck and Co. Inc. - Overview
- Merck and Co. Inc. - Business segments
- Merck and Co. Inc. - Key offerings
- Merck and Co. Inc. - Key customers
- Merck and Co. Inc. - Segment focus
- Mylan NV - Overview
- Mylan NV - Business segments
- Mylan NV - Key offerings
- Mylan NV - Key customers
- Mylan NV - Segment focus
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key offerings
- Novartis AG - Key customers
- Novartis AG - Segment focus
- Teva Pharmaceutical Industries Ltd. - Overview
- Teva Pharmaceutical Industries Ltd. - Business segments
- Teva Pharmaceutical Industries Ltd. - Key offerings
- Teva Pharmaceutical Industries Ltd. - Key customers
- Teva Pharmaceutical Industries Ltd. - Segment focus
- Currency conversion rates for US$
- Research Methodology
- Validation techniques employed for market sizing
- Information sources
- List of abbreviations
Executive Summary
The publisher recognizes the following companies as the key players in the global chemotherapy-induced nausea and vomiting drugs market: Aurobindo Pharma Ltd., Cipla Inc., Dr. Reddys Laboratories Ltd., GlaxoSmithKline Plc, Heron Therapeutics Inc., Merck and Co. Inc., Glenmark Pharmaceuticals Ltd., Mylan NV, Novartis AG, and Teva Pharmaceutical Industries Ltd.Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is the approval of new drugs.`
According to the report, one of the major drivers for this market is the growing cancer population.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aurobindo Pharma Ltd.
- Cipla Inc.
- Dr. Reddys Laboratories Ltd.
- GlaxoSmithKline Plc
- Heron Therapeutics Inc.
- Merck and Co. Inc.
- Glenmark Pharmaceuticals Ltd.
- Mylan NV
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
